Mario Alberto Accardi, PhD, MEng
Co-Founder & Chief Executive Officer Orexia Therapeutics
Mario Alberto Accardi, PhD, MEng, is Co-Founder and Chief Executive Officer of Orexia Therapeutics (previously Orexia and Inexia). He co-founded and launched the company alongside venture capital fund Medicxi and biopharmaceutical company Sosei Heptares in 2019. Under Mario’s leadership, Orexia Therapeutics progressed from an idea, to a company with multiple orexin agonist programs and enabling technology collaborations.
Previously, Mario was a venture capitalist, most recently as a Venture Partner with Fort Rock Capital where he served on the Boards of vasopharm GmbH and GNS Healthcare. Prior to that, he was part of the life sciences investment team at Entrepreneurs Fund whose notable investments include Optinose (NASDAQ: OPTN) and Prosonix (acquired by Circassia). Mario started his career in strategy consulting with Deallus Consulting.
Mario is a graduate of Imperial College London. He holds a Postgraduate in Genomic Medicine, a PhD in Biomedical Engineering and a First-Class Honours MEng Degree in Mechanical Engineering where he focused on Biomedical.
Mario is the Executive Chairman and Co-Founder of Orthonika, Ltd. He serves on the Board of Embody Orthopaedic and on the Strategic Advisory Board of G3 Therapeutics.
Read more here about Orexia Therapeutics